Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| F32AA015647-01A1 | U.S. NIH Grant/Contract | View source | |
| 1F32AA015647-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Study was a F32 Fellowship. Trial was proposed however Principle Investigator does not believe trial took place.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The two purposes of this study are
to determine what effect the chronic and moderate/heavy drinking of alcoholic beverages has
to determine what effect a normal and common (25% frequency) genetic variation of a specific liver enzyme (that breaks down bupropion) has
Two groups of volunteers will be recruited for this study:
Volunteers will NOT be asked to change their drinking (or nondrinking) habits during the study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Trial Withdrawn 2 | Other | Trial Withdrawn 2 |
|
| Trial Withdrawn 1 | Other | Trial Withdrawn 1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Trial Withdrawn 1 | Other | Trial Withdrawn 1 |
| |
| Trial Withdrawn 2 |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David J. Greenblatt, MD | Tufts University; Chair of Department of Pharmacology and Experimental Therapeutics, Sackler School | Principal Investigator |
| Michael H. Court, BVsc, PhD | Tufts University, Department of Pharmacology and Experimental Therapeutics, Sackler School | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tufts University School of Medicine | Boston | Massachusetts | 02111 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 10997936 | Background | Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 2000 Oct;28(10):1176-83. | |
| 15083067 | Background | Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, Court MH. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics. 2004 Apr;14(4):225-38. doi: 10.1097/00008571-200404000-00002. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000428 | Alcohol Drinking |
| D003863 | Depression |
| D016540 | Smoking Cessation |
| D001289 | Attention Deficit Disorder with Hyperactivity |
| D012907 | Smoking |
| ID | Term |
|---|---|
| D004327 | Drinking Behavior |
| D001519 | Behavior |
| D001526 | Behavioral Symptoms |
| D015438 | Health Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Other |
Trial Withdrawn 2 |
|
| D019958 |
| Attention Deficit and Disruptive Behavior Disorders |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |